Mbcr-abl FRT with RNA RT-PCR (CE) | TR-O1

Mbcr-abl FRT with RNA RT-PCR | TR-O1 is available for delivery

Description:

General information: Real Time PCR test for quantification of mRNA gene bcr-abl and gene abl with total RNA extraction kit

Target Disease Type: Oncological diseases

Specific Application: Chronic myelogenous leukaemia: Mbcr-abl

Storage and Shipping : 4 weeks

Mbcr-abl FRT with RNA RT-PCR (CE) TR-O1 DataSheet

INTENDED USE

BCR-ABL M-bcr Real-TM Quant is a Real-Time test for detection and quantification of mRNA chimeric gene bcr-abl (M-bcr) and mRNA gene abl in the clinical material by Real Time PCR. BCR-ABL M-bcr Real-TM Quant kit can be used for screening of CML (chronic myeloid leukemia) associated with chromosomal translocation of M-bcr-abl, to confirm the CML diagnosis, for monitoring a minimal residual disease (MRD) and for the effectiveness of the therapy.

This kit contains reagents for 50 tests for quantitative detection (2 repetitions for sample) or 100 tests (120 extractions, 120 reverse transcriptions and 360 PCR) for qualitative (screening) detection. BCR-ABL M-bcr Real-TM Quant kit contains all the reagents for the isolation of total RNA, reverse transcription of the RNA in cDNA and real time amplification.

PRINCIPLE OF ASSAY

BCR-ABL M-bcr Real-TM Quant is based on three major processes:

1. isolation of total RNA from specimens: isolation procedure is based to the RNA isolation method developed by Chomczynski.
2. reverse transcription of the RNA;
3. real time PCR with two mixes of the oligonucleotides: amplification of mRNA of the chimeric gene M-bcr-abl (p210), corresponding to the region of the fusion abl and bcr genes (b2a2 and b3a2) and a fragment of mRNA of splicing region of abl gene (recommended by the working group "Europe Against Cancer", EAC), as an endogenous internal control and gene-normalizer.

The result of amplification is detected on fluorescence channel Yellow /JOE/HEX. Standard curves with known concentrations of both the endogenous ABL control and the BCR-ABL m-bcr fusion cDNA allow the calculation of the ratio of BCR-ABL m-bcr fusion transcript signal to endogenous ABL signal in each sample. Use of endogenous internal control allows to monitor all the stages of analysis (sampling, transportation, storage, extraction of RNA, reverse transcription of RNA and amplification of cDNA), as well as to count precisely the number of chimeric mRNA bcr-abl gene, taking into account the number and quality of clinical material (normalization).